reptides › focus › dihexa

dihexa

rodent nootropic with zero human trials and a mechanism that's a named oncology concern.

tier D · focus · HGF mimetic · research

verdict

rodent nootropic with zero human trials and a mechanism (c-Met activation) that's a named oncology proliferation pathway.

if you're asking whether dihexa improves cognition in humans — unknown. zero clinical trials have been run on dihexa specifically. community users report subjective cognitive effects within days, but those reports are uncontrolled, unblinded, and indistinguishable from placebo or stack stimulants. the synaptogenesis is real in rats; whether it translates to humans is not what the evidence base addresses.

if you're asking about the c-Met / cancer-pathway concern — c-Met is one of the most thoroughly documented oncology proliferation pathways in modern cancer biology. approved cancer drugs exist to inhibit it. activating it chronically in healthy adults with no human PK data is not a rounding error. this is the live safety question on dihexa and it remains unanswered for the gray-market product.

if you came in via the Athira / fosgonimeton story — Athira advanced fosgonimeton, not dihexa itself, and then moved away from that program after late-stage Alzheimer's readouts failed. the gray-market product is not validated by Athira's clinical history. the '7 orders of magnitude more potent than BDNF' figure is in the Harding lab's published literature, not independently replicated at that scale.

based on published evidence and disclosed clinical practice. not medical advice.

why D-tier

D-tier because the human benefit is unproven (zero trials) and the mechanism carries a specific, named oncology concern that hasn't been characterized in humans. This isn't a 'we don't know' evidence gap. It's a 'we have strong mechanistic reason to worry about a specific pathway' situation. Not F-tier because the underlying research is legitimate. The science is real. Dihexa specifically has no human program, and the related fosgonimeton program no longer rescues the gray-market narrative.

the core tension

Dihexa is a real research compound, developed in Joseph Harding's lab at Washington State University as a small-molecule angiotensin IV analog, and the preclinical synaptogenesis data is genuine. The problem is what drives that synaptogenesis: HGF/c-Met receptor activation. HGF/c-Met signaling is one of the most thoroughly documented proliferation pathways in oncology, tumors hijack it to grow and metastasize. Activating that pathway systemically, chronically, in uncontrolled human dosing, with zero human trials, is not a small thing to hand-wave past. Athira Pharma advanced fosgonimeton instead of dihexa itself, then paused that neurodegeneration program after failed late-stage readouts and rebranded to LeonaBio.

what it is

dihexa is a small-molecule angiotensin IV analog out of Joseph Harding's lab at Washington State University, designed for oral bioavailability and blood-brain barrier penetration. It binds and activates HGF via the c-Met receptor, driving synaptogenesis in rodent hippocampal neurons. Despite the name, it isn't a standard peptide.

what it does

in rodent brain slices and aged-rodent behavior tasks, dihexa increases spine density and improves memory performance at very low concentrations. The Harding lab's 'seven orders of magnitude more potent than BDNF' figure is in the published literature, just not independently replicated at that scale. Community users report subjective cognitive effects within days, but those reports are uncontrolled, unblinded, and indistinguishable from placebo or stack stimulants.

origin

developed at Washington State University, with major preclinical papers in 2012-2014. Licensed to M3 Biotechnology, which became Athira Pharma. Athira's clinical program advanced fosgonimeton (ATH-1017) instead of dihexa itself through phase 2/3 Alzheimer's trials. The pivotal LIFT-AD readout failed in September 2024: GST -0.08, p=0.70; ADAS-Cog11 -1.09 vs -0.39, p=0.35. Athira paused fosgonimeton entirely, laid off ~70% of staff, and rebranded to LeonaBio in January 2026 after pivoting to a breast-cancer asset.

why researchers are interested

the marketing is potency math, the BDNF comparison is genuinely in the literature, and oral bioavailability is unusual in the peptide space. Anecdotal reports of focus and memory effects circulate in nootropic stacks. Rodent data exists and is real, which is enough to keep grey-market interest alive.

does it work

the synaptogenesis is real in rats. Whether it translates to humans is unknown, because zero clinical trials have been run on dihexa specifically. The harder problem is the mechanism: c-Met is one of the most thoroughly documented oncology proliferation pathways in modern cancer biology, and approved cancer drugs exist to inhibit it. Activating it chronically in healthy adults with no human PK data is not a rounding error. Athira advanced fosgonimeton, not dihexa itself, and then moved away from that program after late-stage Alzheimer's readouts failed. The gray-market product is not validated by Athira's clinical history.

claims vs the data

  • produces massive synaptogenesis in hippocampal neurons — partially true — Demonstrated in rodent brain slices and in vivo rodent studies. The specific magnitude claimed in marketing, 'seven orders of magnitude more potent than BDNF', comes from the discoverer's own papers and hasn't been independently replicated at that scale.
  • enhances memory and cognition in humans — weak — Zero human trials. All human claims are extrapolated from rodent behavior and anecdotal community reports with no controls.
  • safe based on rodent studies — weak — Rodent studies used specific dosing protocols for weeks-to-months, not the long-term human exposure implied by nootropic stack use. Safety extrapolation isn't warranted.
  • no cancer concern because it's not directly mutagenic — overreach — c-Met activation is a documented proliferation pathway. Not being directly mutagenic is not the same as not being pro-oncogenic, particularly in users with undetected dysplasia or cancer-predisposing mutations.
  • Athira is developing it as a drug — contradicted — Athira developed the related compound fosgonimeton, not dihexa itself. The distinction matters, and the later fosgonimeton program did not produce a clean late-stage win.

key facts

  • molecular formula: C28H45N3O5
  • molecular weight: 503.68 Da
  • amino acids: modified structure, N-hexanoic-Tyr-Ile-(6)aminohexanoic amide, not a standard amino acid peptide
  • half-life: not characterized in humans; oral bioavailability demonstrated in rodent models
  • type: small-molecule angiotensin IV analog (not a standard peptide despite the naming)
  • CAS: 1401708-83-5
  • 0 human clinical trials of dihexa specifically
  • c-Met the receptor dihexa activates (oncology pathway)
  • fosgonimeton related compound Athira took to humans, then paused
  • rodent hippocampus where all the major efficacy data comes from

frequently asked questions

What is Dihexa?

Dihexa is a synthetic small molecule developed from angiotensin IV research at Washington State University. It activates the hepatocyte growth factor (HGF) and c-Met receptor pathway, driving synaptogenesis in preclinical rodent models.

What does Dihexa do?

Dihexa produces measurable synaptogenesis, new synaptic connections, in rodent hippocampal neurons, with very high potency compared to endogenous BDNF signaling. Community users report cognitive effects within days of use. Human clinical trials of dihexa specifically have not been conducted, so the translation of these preclinical findings to humans remains unproven.

How is Dihexa typically administered?

Dihexa is orally bioavailable, unlike most peptides; the research-peptide community discusses sublingual or oral routes. There is no FDA-approved dosing protocol.

What are the side effects of Dihexa?

Short-term community reports are mild, occasional headaches, sleep changes. The serious concern with Dihexa is theoretical: the c-Met/HGF pathway it activates is centrally involved in cancer proliferation and metastasis. Chronic activation of this pathway in healthy adults, without monitoring, carries cancer-risk implications that haven't been characterized in humans.

Is Dihexa FDA approved?

No. Dihexa has no FDA approval and no registered human clinical trials. The developer's pharmaceutical spinoff (Athira Pharma) chose a related compound (fosgonimeton) for clinical development rather than dihexa itself, and later moved away from that neurodegeneration program after failed late-stage readouts.

How much does Dihexa cost?

No clinical retail price. On the research-chemical market it is among the more expensive nootropic research chemicals due to synthesis complexity.

related peptides

  • semax — actual community nootropic with human data
  • selank — other research-backed nootropic peptide
  • pinealon — russian-origin nootropic peptide with small clinical trial base, parallel to dihexa's WSU research vs. the pharma-development gap

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.